score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat29		
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G669E	0.3158	171.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0	0.0	0.0	0.0	FLT3 p.G669E (Missense)	1.0	MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E240K	0.3388	307.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0	0.0	0.0	0.0	FLT3 p.E240K (Missense)	1.0	MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G1304E	0.2477	218.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0	0.0	0.0	0.0	ALK p.G1304E (Missense)		MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K1203E	0.3132	182.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	SETBP1 p.K1203E (Missense)		MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2120K	0.3468	447.0	0.0	0.0																					0	0.0	0.0	0.0	ROS1 p.E2120K (Missense)		MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1933K	0.2821	117.0	0.0	0.0																					0	0.0	0.0	0.0	ROS1 p.E1933K (Missense)		MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1204L	0.3631	168.0	0.0	0.0																					0	0.0	0.0	0.0	COL1A1 p.P1204L (Missense)		MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Biologically Relevant				Somatic Variant	ERG	Missense	p.S331N	0.3758	157.0	0.0	0.0																					0	0.0	0.0	0.0	ERG p.S331N (Missense)		MEL-IPI_Pat29	MEL-IPI_Pat29-Tumor-SM-4DK1P	MEL-IPI_Pat29-Normal-SM-4NFUV
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat29		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.737																									0				COSMIC Signature (version 2) 7 (74%)		MEL-IPI_Pat29		
